Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study
Identifieur interne : 000042 ( Pmc/Corpus ); précédent : 000041; suivant : 000043Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study
Auteurs : Kai-Jieh Yeo ; Hsin-Hua Chen ; Yi-Ming Chen ; Ching-Heng Lin ; Der-Yuan Chen ; Chih-Ming Lai ; Wen-Cheng ChaoSource :
- BMC Infectious Diseases [ 1471-2334 ] ; 2020.
Abstract
Pneumocystis pneumonia (PCP) is increasingly being diagnosed in patients with systemic lupus erythematosus (SLE), and hydroxychloroquine (HCQ) has been found to possess antifungal activities. We hence aimed to investigate the association between HCQ and PCP risk among patients with SLE.
Using the 1997–2013 nationwide claim data, we identified 24,343 newly-diagnosed SLE patients. We then identified 58 PCP cases and selected 348 non-PCP controls matching (1:6) by age, sex, disease duration and the year of PCP diagnosis date. The risk of PCP was assessed by determing odds ratios (ORs) with 95% confidence intervals (CIs) by using multivariable conditional logistic regression.
The risk of PCP was associated with moderate to severe renal disease (OR 6.73, 95% CI 1.98–22.92), higher doses of glucocorticoids (≤5 mg/day, reference; 5–10 mg/day, OR 25.88, 95% CI 2.97–225.33; > 10 mg/day, OR 286.58, 95% CI 28.58–> 999), higher 3-month cumulative dose of cyclophosphamide (not use, reference; ≤1.4 g, OR 0.64, 95% CI 0.14–3.01; > 1.4 g, OR 11.52, 95% CI 1.97–67.39) and use of mycophenolate mofetil/mycophenolic acid (OR 50.79, 95% CI 5.32–484.77), whereas 3-month cumulative dose of HCQ was associated with a reduced risk of PCP among patients with SLE (not use, reference; ≤14 g, OR 0.69, 95% CI 0.21–2.24; > 14 g, OR 0.20, 95% CI 0.05–0.71).
This study demonstrated incident PCP was associated with mycophenolate mofetil/mycophenolic acid use and higher doses of cyclophosphamide or glucocorticoid, whereas the use of a higher dose of HCQ was associated with a reduced risk of PCP in lupus patients.
Url:
DOI: 10.1186/s12879-020-4826-1
PubMed: 32041539
PubMed Central: 7011312
Links to Exploration step
PMC:7011312Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study</title><author><name sortKey="Yeo, Kai Jieh" sort="Yeo, Kai Jieh" uniqKey="Yeo K" first="Kai-Jieh" last="Yeo">Kai-Jieh Yeo</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Rheumatology and Immunology Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chen, Hsin Hua" sort="Chen, Hsin Hua" uniqKey="Chen H" first="Hsin-Hua" last="Chen">Hsin-Hua Chen</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Internal Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3749</institution-id><institution-id institution-id-type="GRID">grid.260542.7</institution-id><institution>Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine,</institution><institution>Chung Hsing University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>School of Medicine, National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff6"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>Institute of Public Health and Community Medicine Research Center,</institution><institution>National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff7"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 1428</institution-id><institution-id institution-id-type="GRID">grid.265231.1</institution-id><institution>Department of Industrial Engineering and Enterprise Information,</institution><institution>Tung Hai University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chen, Yi Ming" sort="Chen, Yi Ming" uniqKey="Chen Y" first="Yi-Ming" last="Chen">Yi-Ming Chen</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Internal Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3749</institution-id><institution-id institution-id-type="GRID">grid.260542.7</institution-id><institution>Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine,</institution><institution>Chung Hsing University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>School of Medicine, National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Lin, Ching Heng" sort="Lin, Ching Heng" uniqKey="Lin C" first="Ching-Heng" last="Lin">Ching-Heng Lin</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff8"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0416</institution-id><institution-id institution-id-type="GRID">grid.412146.4</institution-id><institution>Department of Healthcare Management,</institution><institution>National Taipei University of Nursing and Health Sciences,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff9">Department of Public Health, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chen, Der Yuan" sort="Chen, Der Yuan" uniqKey="Chen D" first="Der-Yuan" last="Chen">Der-Yuan Chen</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Rheumatology and Immunology Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff10"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Translational Medicine Laboratory, Rheumatic Diseases Research Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff11"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution>School of Medicine,</institution><institution>China Medical University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Lai, Chih Ming" sort="Lai, Chih Ming" uniqKey="Lai C" first="Chih-Ming" last="Lai">Chih-Ming Lai</name><affiliation><nlm:aff id="Aff12"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Critical Care Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff13"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Neurosurgery,</institution><institution>Neurological Institute, Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chao, Wen Cheng" sort="Chao, Wen Cheng" uniqKey="Chao W" first="Wen-Cheng" last="Chao">Wen-Cheng Chao</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff7"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 1428</institution-id><institution-id institution-id-type="GRID">grid.265231.1</institution-id><institution>Department of Industrial Engineering and Enterprise Information,</institution><institution>Tung Hai University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff12"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Critical Care Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff14"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9193 1222</institution-id><institution-id institution-id-type="GRID">grid.412038.c</institution-id><institution>Department of Business Administration,</institution><institution>National Changhua University of Education,</institution></institution-wrap>Changhua, Taiwan</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32041539</idno><idno type="pmc">7011312</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011312</idno><idno type="RBID">PMC:7011312</idno><idno type="doi">10.1186/s12879-020-4826-1</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000042</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000042</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study</title><author><name sortKey="Yeo, Kai Jieh" sort="Yeo, Kai Jieh" uniqKey="Yeo K" first="Kai-Jieh" last="Yeo">Kai-Jieh Yeo</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Rheumatology and Immunology Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chen, Hsin Hua" sort="Chen, Hsin Hua" uniqKey="Chen H" first="Hsin-Hua" last="Chen">Hsin-Hua Chen</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Internal Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3749</institution-id><institution-id institution-id-type="GRID">grid.260542.7</institution-id><institution>Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine,</institution><institution>Chung Hsing University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>School of Medicine, National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff6"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>Institute of Public Health and Community Medicine Research Center,</institution><institution>National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff7"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 1428</institution-id><institution-id institution-id-type="GRID">grid.265231.1</institution-id><institution>Department of Industrial Engineering and Enterprise Information,</institution><institution>Tung Hai University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chen, Yi Ming" sort="Chen, Yi Ming" uniqKey="Chen Y" first="Yi-Ming" last="Chen">Yi-Ming Chen</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Internal Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3749</institution-id><institution-id institution-id-type="GRID">grid.260542.7</institution-id><institution>Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine,</institution><institution>Chung Hsing University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>School of Medicine, National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Lin, Ching Heng" sort="Lin, Ching Heng" uniqKey="Lin C" first="Ching-Heng" last="Lin">Ching-Heng Lin</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff8"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0416</institution-id><institution-id institution-id-type="GRID">grid.412146.4</institution-id><institution>Department of Healthcare Management,</institution><institution>National Taipei University of Nursing and Health Sciences,</institution></institution-wrap>Taipei, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff9">Department of Public Health, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chen, Der Yuan" sort="Chen, Der Yuan" uniqKey="Chen D" first="Der-Yuan" last="Chen">Der-Yuan Chen</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Rheumatology and Immunology Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff10"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Translational Medicine Laboratory, Rheumatic Diseases Research Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff11"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution>School of Medicine,</institution><institution>China Medical University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Lai, Chih Ming" sort="Lai, Chih Ming" uniqKey="Lai C" first="Chih-Ming" last="Lai">Chih-Ming Lai</name><affiliation><nlm:aff id="Aff12"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Critical Care Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff13"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Neurosurgery,</institution><institution>Neurological Institute, Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chao, Wen Cheng" sort="Chao, Wen Cheng" uniqKey="Chao W" first="Wen-Cheng" last="Chao">Wen-Cheng Chao</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff7"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 1428</institution-id><institution-id institution-id-type="GRID">grid.265231.1</institution-id><institution>Department of Industrial Engineering and Enterprise Information,</institution><institution>Tung Hai University,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff12"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Critical Care Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="Aff14"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9193 1222</institution-id><institution-id institution-id-type="GRID">grid.412038.c</institution-id><institution>Department of Business Administration,</institution><institution>National Changhua University of Education,</institution></institution-wrap>Changhua, Taiwan</nlm:aff></affiliation></author></analytic><series><title level="j">BMC Infectious Diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p id="Par1">Pneumocystis pneumonia (PCP) is increasingly being diagnosed in patients with systemic lupus erythematosus (SLE), and hydroxychloroquine (HCQ) has been found to possess antifungal activities. We hence aimed to investigate the association between HCQ and PCP risk among patients with SLE.</p></sec><sec><title>Methods</title><p id="Par2">Using the 1997–2013 nationwide claim data, we identified 24,343 newly-diagnosed SLE patients. We then identified 58 PCP cases and selected 348 non-PCP controls matching (1:6) by age, sex, disease duration and the year of PCP diagnosis date. The risk of PCP was assessed by determing odds ratios (ORs) with 95% confidence intervals (CIs) by using multivariable conditional logistic regression.</p></sec><sec><title>Results</title><p id="Par3">The risk of PCP was associated with moderate to severe renal disease (OR 6.73, 95% CI 1.98–22.92), higher doses of glucocorticoids (≤5 mg/day, reference; 5–10 mg/day, OR 25.88, 95% CI 2.97–225.33; > 10 mg/day, OR 286.58, 95% CI 28.58–> 999), higher 3-month cumulative dose of cyclophosphamide (not use, reference; ≤1.4 g, OR 0.64, 95% CI 0.14–3.01; > 1.4 g, OR 11.52, 95% CI 1.97–67.39) and use of mycophenolate mofetil/mycophenolic acid (OR 50.79, 95% CI 5.32–484.77), whereas 3-month cumulative dose of HCQ was associated with a reduced risk of PCP among patients with SLE (not use, reference; ≤14 g, OR 0.69, 95% CI 0.21–2.24; > 14 g, OR 0.20, 95% CI 0.05–0.71).</p></sec><sec><title>Conclusions</title><p id="Par4">This study demonstrated incident PCP was associated with mycophenolate mofetil/mycophenolic acid use and higher doses of cyclophosphamide or glucocorticoid, whereas the use of a higher dose of HCQ was associated with a reduced risk of PCP in lupus patients.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Fillatre, P" uniqKey="Fillatre P">P Fillatre</name></author><author><name sortKey="Decaux, O" uniqKey="Decaux O">O Decaux</name></author><author><name sortKey="Jouneau, S" uniqKey="Jouneau S">S Jouneau</name></author><author><name sortKey="Revest, M" uniqKey="Revest M">M Revest</name></author><author><name sortKey="Gacouin, A" uniqKey="Gacouin A">A Gacouin</name></author><author><name sortKey="Robert Gangneux, F" uniqKey="Robert Gangneux F">F Robert-Gangneux</name></author><author><name sortKey="Fresnel, A" uniqKey="Fresnel A">A Fresnel</name></author><author><name sortKey="Guiguen, C" uniqKey="Guiguen C">C Guiguen</name></author><author><name sortKey="Le Tulzo, Y" uniqKey="Le Tulzo Y">Y Le Tulzo</name></author><author><name sortKey="Jego, P" uniqKey="Jego P">P Jego</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schmidt, Jj" uniqKey="Schmidt J">JJ Schmidt</name></author><author><name sortKey="Lueck, C" uniqKey="Lueck C">C Lueck</name></author><author><name sortKey="Ziesing, S" uniqKey="Ziesing S">S Ziesing</name></author><author><name sortKey="Stoll, M" uniqKey="Stoll M">M Stoll</name></author><author><name sortKey="Haller, H" uniqKey="Haller H">H Haller</name></author><author><name sortKey="Gottlieb, J" uniqKey="Gottlieb J">J Gottlieb</name></author><author><name sortKey="Eder, M" uniqKey="Eder M">M Eder</name></author><author><name sortKey="Welte, T" uniqKey="Welte T">T Welte</name></author><author><name sortKey="Hoeper, Mm" uniqKey="Hoeper M">MM Hoeper</name></author><author><name sortKey="Scherag, A" uniqKey="Scherag A">A Scherag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pryor, Bd" uniqKey="Pryor B">BD Pryor</name></author><author><name sortKey="Bologna, Sg" uniqKey="Bologna S">SG Bologna</name></author><author><name sortKey="Kahl, Le" uniqKey="Kahl L">LE Kahl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rolain, Jm" uniqKey="Rolain J">JM Rolain</name></author><author><name sortKey="Colson, P" uniqKey="Colson P">P Colson</name></author><author><name sortKey="Raoult, D" uniqKey="Raoult D">D Raoult</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Wan, Z" uniqKey="Wan Z">Z Wan</name></author><author><name sortKey="Liu, W" uniqKey="Liu W">W Liu</name></author><author><name sortKey="Li, R" uniqKey="Li R">R Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Gigliotti, F" uniqKey="Gigliotti F">F Gigliotti</name></author><author><name sortKey="Bhagwat, Sp" uniqKey="Bhagwat S">SP Bhagwat</name></author><author><name sortKey="George, Tc" uniqKey="George T">TC George</name></author><author><name sortKey="Wright, Tw" uniqKey="Wright T">TW Wright</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nunokawa, T" uniqKey="Nunokawa T">T Nunokawa</name></author><author><name sortKey="Yokogawa, N" uniqKey="Yokogawa N">N Yokogawa</name></author><author><name sortKey="Shimada, K" uniqKey="Shimada K">K Shimada</name></author><author><name sortKey="Sugii, S" uniqKey="Sugii S">S Sugii</name></author><author><name sortKey="Nishino, J" uniqKey="Nishino J">J Nishino</name></author><author><name sortKey="Gosho, M" uniqKey="Gosho M">M Gosho</name></author><author><name sortKey="Wagatsuma, Y" uniqKey="Wagatsuma Y">Y Wagatsuma</name></author><author><name sortKey="Tohma, S" uniqKey="Tohma S">S Tohma</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Maschmeyer, G" uniqKey="Maschmeyer G">G Maschmeyer</name></author><author><name sortKey="Helweg Larsen, J" uniqKey="Helweg Larsen J">J Helweg-Larsen</name></author><author><name sortKey="Pagano, L" uniqKey="Pagano L">L Pagano</name></author><author><name sortKey="Robin, C" uniqKey="Robin C">C Robin</name></author><author><name sortKey="Cordonnier, C" uniqKey="Cordonnier C">C Cordonnier</name></author><author><name sortKey="Schellongowski, P" uniqKey="Schellongowski P">P Schellongowski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feldman, Ch" uniqKey="Feldman C">CH Feldman</name></author><author><name sortKey="Hiraki, Lt" uniqKey="Hiraki L">LT Hiraki</name></author><author><name sortKey="Winkelmayer, Wc" uniqKey="Winkelmayer W">WC Winkelmayer</name></author><author><name sortKey="Marty, Fm" uniqKey="Marty F">FM Marty</name></author><author><name sortKey="Franklin, Jm" uniqKey="Franklin J">JM Franklin</name></author><author><name sortKey="Kim, Sc" uniqKey="Kim S">SC Kim</name></author><author><name sortKey="Costenbader, Kh" uniqKey="Costenbader K">KH Costenbader</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deyo, Ra" uniqKey="Deyo R">RA Deyo</name></author><author><name sortKey="Cherkin, Dc" uniqKey="Cherkin D">DC Cherkin</name></author><author><name sortKey="Ciol, Ma" uniqKey="Ciol M">MA Ciol</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vrieze, Si" uniqKey="Vrieze S">SI Vrieze</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Avina Zubieta, Ja" uniqKey="Avina Zubieta J">JA Avina-Zubieta</name></author><author><name sortKey="Galindo Rodriguez, G" uniqKey="Galindo Rodriguez G">G Galindo-Rodriguez</name></author><author><name sortKey="Newman, S" uniqKey="Newman S">S Newman</name></author><author><name sortKey="Suarez Almazor, Me" uniqKey="Suarez Almazor M">ME Suarez-Almazor</name></author><author><name sortKey="Russell, As" uniqKey="Russell A">AS Russell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ruiz Irastorza, G" uniqKey="Ruiz Irastorza G">G Ruiz-Irastorza</name></author><author><name sortKey="Olivares, N" uniqKey="Olivares N">N Olivares</name></author><author><name sortKey="Ruiz Arruza, I" uniqKey="Ruiz Arruza I">I Ruiz-Arruza</name></author><author><name sortKey="Martinez Berriotxoa, A" uniqKey="Martinez Berriotxoa A">A Martinez-Berriotxoa</name></author><author><name sortKey="Egurbide, Mv" uniqKey="Egurbide M">MV Egurbide</name></author><author><name sortKey="Aguirre, C" uniqKey="Aguirre C">C Aguirre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Siso, A" uniqKey="Siso A">A Siso</name></author><author><name sortKey="Ramos Casals, M" uniqKey="Ramos Casals M">M Ramos-Casals</name></author><author><name sortKey="Bove, A" uniqKey="Bove A">A Bove</name></author><author><name sortKey="Brito Zeron, P" uniqKey="Brito Zeron P">P Brito-Zeron</name></author><author><name sortKey="Soria, N" uniqKey="Soria N">N Soria</name></author><author><name sortKey="Munoz, S" uniqKey="Munoz S">S Munoz</name></author><author><name sortKey="Testi, A" uniqKey="Testi A">A Testi</name></author><author><name sortKey="Plaza, J" uniqKey="Plaza J">J Plaza</name></author><author><name sortKey="Sentis, J" uniqKey="Sentis J">J Sentis</name></author><author><name sortKey="Coca, A" uniqKey="Coca A">A Coca</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Henriet, Ss" uniqKey="Henriet S">SS Henriet</name></author><author><name sortKey="Jans, J" uniqKey="Jans J">J Jans</name></author><author><name sortKey="Simonetti, E" uniqKey="Simonetti E">E Simonetti</name></author><author><name sortKey="Kwon Chung, Kj" uniqKey="Kwon Chung K">KJ Kwon-Chung</name></author><author><name sortKey="Rijs, Aj" uniqKey="Rijs A">AJ Rijs</name></author><author><name sortKey="Hermans, Pw" uniqKey="Hermans P">PW Hermans</name></author><author><name sortKey="Holland, Sm" uniqKey="Holland S">SM Holland</name></author><author><name sortKey="De Jonge, Mi" uniqKey="De Jonge M">MI de Jonge</name></author><author><name sortKey="Warris, A" uniqKey="Warris A">A Warris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Podrebarac, Ta" uniqKey="Podrebarac T">TA Podrebarac</name></author><author><name sortKey="Jovaisas, A" uniqKey="Jovaisas A">A Jovaisas</name></author><author><name sortKey="Karsh, J" uniqKey="Karsh J">J Karsh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gupta, D" uniqKey="Gupta D">D Gupta</name></author><author><name sortKey="Zachariah, A" uniqKey="Zachariah A">A Zachariah</name></author><author><name sortKey="Roppelt, H" uniqKey="Roppelt H">H Roppelt</name></author><author><name sortKey="Patel, Am" uniqKey="Patel A">AM Patel</name></author><author><name sortKey="Gruber, Bl" uniqKey="Gruber B">BL Gruber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kapoor, Tm" uniqKey="Kapoor T">TM Kapoor</name></author><author><name sortKey="Mahadeshwar, P" uniqKey="Mahadeshwar P">P Mahadeshwar</name></author><author><name sortKey="Nguyen, S" uniqKey="Nguyen S">S Nguyen</name></author><author><name sortKey="Li, J" uniqKey="Li J">J Li</name></author><author><name sortKey="Kapoor, S" uniqKey="Kapoor S">S Kapoor</name></author><author><name sortKey="Bathon, J" uniqKey="Bathon J">J Bathon</name></author><author><name sortKey="Giles, J" uniqKey="Giles J">J Giles</name></author><author><name sortKey="Askanase, A" uniqKey="Askanase A">A Askanase</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weng, Ct" uniqKey="Weng C">CT Weng</name></author><author><name sortKey="Liu, Mf" uniqKey="Liu M">MF Liu</name></author><author><name sortKey="Weng, My" uniqKey="Weng M">MY Weng</name></author><author><name sortKey="Lee, Ny" uniqKey="Lee N">NY Lee</name></author><author><name sortKey="Wang, Mc" uniqKey="Wang M">MC Wang</name></author><author><name sortKey="Lin, Wc" uniqKey="Lin W">WC Lin</name></author><author><name sortKey="Ou, Cy" uniqKey="Ou C">CY Ou</name></author><author><name sortKey="Lai, Ww" uniqKey="Lai W">WW Lai</name></author><author><name sortKey="Hsu, Sc" uniqKey="Hsu S">SC Hsu</name></author><author><name sortKey="Chao, Sc" uniqKey="Chao S">SC Chao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feldman, Ch" uniqKey="Feldman C">CH Feldman</name></author><author><name sortKey="Marty, Fm" uniqKey="Marty F">FM Marty</name></author><author><name sortKey="Winkelmayer, Wc" uniqKey="Winkelmayer W">WC Winkelmayer</name></author><author><name sortKey="Guan, H" uniqKey="Guan H">H Guan</name></author><author><name sortKey="Franklin, Jm" uniqKey="Franklin J">JM Franklin</name></author><author><name sortKey="Solomon, Dh" uniqKey="Solomon D">DH Solomon</name></author><author><name sortKey="Costenbader, Kh" uniqKey="Costenbader K">KH Costenbader</name></author><author><name sortKey="Kim, Sc" uniqKey="Kim S">SC Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ginzler, Em" uniqKey="Ginzler E">EM Ginzler</name></author><author><name sortKey="Dooley, Ma" uniqKey="Dooley M">MA Dooley</name></author><author><name sortKey="Aranow, C" uniqKey="Aranow C">C Aranow</name></author><author><name sortKey="Kim, My" uniqKey="Kim M">MY Kim</name></author><author><name sortKey="Buyon, J" uniqKey="Buyon J">J Buyon</name></author><author><name sortKey="Merrill, Jt" uniqKey="Merrill J">JT Merrill</name></author><author><name sortKey="Petri, M" uniqKey="Petri M">M Petri</name></author><author><name sortKey="Gilkeson, Gs" uniqKey="Gilkeson G">GS Gilkeson</name></author><author><name sortKey="Wallace, Dj" uniqKey="Wallace D">DJ Wallace</name></author><author><name sortKey="Weisman, Mh" uniqKey="Weisman M">MH Weisman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Ll" uniqKey="Liu L">LL Liu</name></author><author><name sortKey="Jiang, Y" uniqKey="Jiang Y">Y Jiang</name></author><author><name sortKey="Wang, Ln" uniqKey="Wang L">LN Wang</name></author><author><name sortKey="Yao, L" uniqKey="Yao L">L Yao</name></author><author><name sortKey="Li, Zl" uniqKey="Li Z">ZL Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mok, Cc" uniqKey="Mok C">CC Mok</name></author><author><name sortKey="Tse, Sm" uniqKey="Tse S">SM Tse</name></author><author><name sortKey="Chan, Kl" uniqKey="Chan K">KL Chan</name></author><author><name sortKey="Ho, Ly" uniqKey="Ho L">LY Ho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Park, Jw" uniqKey="Park J">JW Park</name></author><author><name sortKey="Curtis, Jr" uniqKey="Curtis J">JR Curtis</name></author><author><name sortKey="Moon, J" uniqKey="Moon J">J Moon</name></author><author><name sortKey="Song, Yw" uniqKey="Song Y">YW Song</name></author><author><name sortKey="Kim, S" uniqKey="Kim S">S Kim</name></author><author><name sortKey="Lee, Eb" uniqKey="Lee E">EB Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Park, Jw" uniqKey="Park J">JW Park</name></author><author><name sortKey="Curtis, Jr" uniqKey="Curtis J">JR Curtis</name></author><author><name sortKey="Kim, Mj" uniqKey="Kim M">MJ Kim</name></author><author><name sortKey="Lee, H" uniqKey="Lee H">H Lee</name></author><author><name sortKey="Song, Yw" uniqKey="Song Y">YW Song</name></author><author><name sortKey="Lee, Eb" uniqKey="Lee E">EB Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, Tm" uniqKey="Cheng T">TM Cheng</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32041539</article-id><article-id pub-id-type="pmc">7011312</article-id><article-id pub-id-type="publisher-id">4826</article-id><article-id pub-id-type="doi">10.1186/s12879-020-4826-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yeo</surname><given-names>Kai-Jieh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Hsin-Hua</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yi-Ming</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ching-Heng</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Der-Yuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lai</surname><given-names>Chih-Ming</given-names></name><address><email>cmlai@vghtc.gov.tw</email></address><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9631-8934</contrib-id><name><surname>Chao</surname><given-names>Wen-Cheng</given-names></name><address><email>cwc081@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Rheumatology and Immunology Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of the Medical Research,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Internal Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3749</institution-id><institution-id institution-id-type="GRID">grid.260542.7</institution-id><institution>Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine,</institution><institution>Chung Hsing University,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>School of Medicine, National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0425 5914</institution-id><institution-id institution-id-type="GRID">grid.260770.4</institution-id><institution>Institute of Public Health and Community Medicine Research Center,</institution><institution>National Yang-Ming University,</institution></institution-wrap>Taipei, Taiwan</aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 1428</institution-id><institution-id institution-id-type="GRID">grid.265231.1</institution-id><institution>Department of Industrial Engineering and Enterprise Information,</institution><institution>Tung Hai University,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0416</institution-id><institution-id institution-id-type="GRID">grid.412146.4</institution-id><institution>Department of Healthcare Management,</institution><institution>National Taipei University of Nursing and Health Sciences,</institution></institution-wrap>Taipei, Taiwan</aff><aff id="Aff9"><label>9</label>Department of Public Health, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan</aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Translational Medicine Laboratory, Rheumatic Diseases Research Center,</institution><institution>China Medical University Hospital,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution>School of Medicine,</institution><institution>China Medical University,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Critical Care Medicine,</institution><institution>Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution>Department of Neurosurgery,</institution><institution>Neurological Institute, Taichung Veterans General Hospital,</institution></institution-wrap>Taichung, Taiwan</aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9193 1222</institution-id><institution-id institution-id-type="GRID">grid.412038.c</institution-id><institution>Department of Business Administration,</institution><institution>National Changhua University of Education,</institution></institution-wrap>Changhua, Taiwan</aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>20</volume><elocation-id>112</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>© The Author(s). 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Pneumocystis pneumonia (PCP) is increasingly being diagnosed in patients with systemic lupus erythematosus (SLE), and hydroxychloroquine (HCQ) has been found to possess antifungal activities. We hence aimed to investigate the association between HCQ and PCP risk among patients with SLE.</p></sec><sec><title>Methods</title><p id="Par2">Using the 1997–2013 nationwide claim data, we identified 24,343 newly-diagnosed SLE patients. We then identified 58 PCP cases and selected 348 non-PCP controls matching (1:6) by age, sex, disease duration and the year of PCP diagnosis date. The risk of PCP was assessed by determing odds ratios (ORs) with 95% confidence intervals (CIs) by using multivariable conditional logistic regression.</p></sec><sec><title>Results</title><p id="Par3">The risk of PCP was associated with moderate to severe renal disease (OR 6.73, 95% CI 1.98–22.92), higher doses of glucocorticoids (≤5 mg/day, reference; 5–10 mg/day, OR 25.88, 95% CI 2.97–225.33; > 10 mg/day, OR 286.58, 95% CI 28.58–> 999), higher 3-month cumulative dose of cyclophosphamide (not use, reference; ≤1.4 g, OR 0.64, 95% CI 0.14–3.01; > 1.4 g, OR 11.52, 95% CI 1.97–67.39) and use of mycophenolate mofetil/mycophenolic acid (OR 50.79, 95% CI 5.32–484.77), whereas 3-month cumulative dose of HCQ was associated with a reduced risk of PCP among patients with SLE (not use, reference; ≤14 g, OR 0.69, 95% CI 0.21–2.24; > 14 g, OR 0.20, 95% CI 0.05–0.71).</p></sec><sec><title>Conclusions</title><p id="Par4">This study demonstrated incident PCP was associated with mycophenolate mofetil/mycophenolic acid use and higher doses of cyclophosphamide or glucocorticoid, whereas the use of a higher dose of HCQ was associated with a reduced risk of PCP in lupus patients.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Lupus</kwd><kwd>Pneumocystis pneumonia</kwd><kwd>Hydroxychloroquine</kwd><kwd>Glucocorticoid</kwd><kwd>Mycophenolate mofetil</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par25">Pneumocystis pneumonia (PCP), caused by <italic>Pneumocystis jirovecii,</italic> is a potentially life-threatening infection and is increasingly diagnosed in the immunocompromised patient without human immunodeficiency virus infection, including transplant recipients and the patient with malignancies or autoimmune diseases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Glucocorticoids (GC) and a number of immunosuppressants, mainly cyclophosphamide, and have been identified to be associated with an increased risk for PCP in patients with systemic lupus erythematosus (SLE) [<xref ref-type="bibr" rid="CR3">3</xref>]. Notably, hydroxychloroquine (HCQ) and sulfasalazine (SSZ) have been found to have anti-fungal activities; therefore, it is crucial to address the risk for PCP in lupus patients receiving HCQ or SSZ [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. One recently published Japanese multicenter study reported a reduced risk for PCP in patients with rheumatoid arthritis (RA) receiving SSZ [<xref ref-type="bibr" rid="CR7">7</xref>]. HCQ is a frequently used medication in patients with SLE; therefore, there is a crucial need to determine the distinct risks for PCP among medications, including HCQ and immunosuppressants, in patients with SLE. In this study, we aimed to explore the individual risks for PCP of frequently administered medications including GC as well as immunosuppressants and to determine the potential protective effect of HCQ against PCP among patients with SLE by using a Taiwanes population-based claim database.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Ethical approval</title><p id="Par26">The present study was approved by the Institutional Review Board of Taichung Veterans General Hospital, Taiwan (CE14149B-3). Written informed consent was waived due to that all of the individual data were de-identified.</p></sec><sec id="Sec4"><title>Study design</title><p id="Par27">The present study was a retrospective case-control study.</p></sec><sec id="Sec5"><title>Data source</title><p id="Par28">The Taiwanese single-payer National Health Insurance (NHI) program was launched in 1995 with wide coverage that approximately 99.5% of Taiwan’s population were enrolled in 2015 [<xref ref-type="bibr" rid="CR8">8</xref>]. The National Health Insurance Research Database (NHIRD) is the database of the aforementioned NHI program containing all of the original claim profiles. In the present study, we used both the inpatient and ambulatory data from the 1997–2013 NHIRD to identify newly-diagnosed lupus patients from 2001 to 2013. Notably, in Taiwan, those with a certain major illness, so-called catastrophic illness, including cancer and a number of autoimmune diseases, including SLE, are exempted from co-payment. Furthermore, NHIRD contains the aforementioned catastrophic illness enrolment profile, and the data of these patients are compiled as the Registry for Catastrophic Illness Patient Database (RCIPD). In the present study, we enrolled lupus patients with detailed data in the RCIPD.</p></sec><sec id="Sec6"><title>Diagnosis of pneumocystis pneumonia</title><p id="Par29">PCP was identified using the International Classification of Diseases (9th Revision) Clinical Modification (ICD-9-CM) codes for PCP (136.3) with the concurrent administration of medications used to treat PCP. Medications (Anatomical Therapeutic Chemical code) for PCP included Trimethoprim-sulfamethoxazole (J01EE01), Trimethoprim (J01EA01), Sulfamethoxazole (J01EC01), Clindamycin (J01FF01), Caspofungin (J02AX04), Micafungin (J02AX05), and Anidulafungin (J02AX06) [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec7"><title>Matched non-PCP lupus subjects</title><p id="Par30">In this study, SLE patients were identified with having a hospital admission or ambulatory visit with a diagnosis of SLE (ICD-9-CM code 710.0) and the catastrophic illness certificate of SLE between 1997 and 2013. The index date of PCP in lupus patients was defined as their first date of the visit with a PCP diagnosis, and their index year was defined as the year of index-date. We randomly selected matched non-PCP lupus subjects among those with SLE but without PCP, matching PCP cases (1:6) for age, gender, disease duration as well as the index year.</p></sec><sec id="Sec8"><title>Covariates</title><p id="Par31">Covariates included in the multivariable conditional logistic regression model consisted of comorbidities and SLE-related medications within 3 months before the index date. Given that lupus nephritis has been implicated with an elevated risk for PCP in lupus patients, covariates regarding comorbid conditions included moderate to severe renal disease and the Charlson comorbidity index (CCI) calculated without inclusion of moderate to severe renal disease [<xref ref-type="bibr" rid="CR10">10</xref>]. The comorbidity was identified as having one inpatient visit or at least three ambulatory visits with a corresponding ICD-9 CM code within one year prior to the defined index-date. The CCI was used to determine the comorbid medical conditions [<xref ref-type="bibr" rid="CR11">11</xref>]. The main focus of this study was to investigate the risk for PCP infection with SLE relevant medications within 3 months before the index date. SLE-related medications included GC (average daily prednisolone equivalent dose ≤5 mg, 5–10 mg, > 10 mg), HCQ (not use, ≤ median 3-month cumulative dose, > median 3-month cumulative dose), SSZ, methotrexate (MTX), leflunomide, and immunosuppressants including cyclophosphamide (CYC) (not use, ≤ median 3-month cumulative dose, > median 3-month cumulative dose), cyclosporine (CS), azathioprine (AZA), and mycophenolate mofetil (MMF)/mycophenolic acid (MPA). Because trimethoprim-sulfamethoxazole was a well-known antibiotic that decreases the risk of PCP development, we also considered its use within 3 months before the index date as a covariate.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par32">Data were presented as numbers (percentages) for categorical variables and the mean ± standard deviation for continuous variables. The differences between the PJP group and non-PJP group were determined by Pearson’s <italic>χ</italic><sup>2</sup> test for categorical variables and Student’s t-test for continuous variables. Multivariable conditional logistic regression were applied to estimate the associations between covariates and the risk of PCP shown as odds ratio (OR) with 95% confidence intervals (CIs). We used forced entering and stepwise selection methods to build two models. Akaike information criterion (AIC) was used to evaluate the relative quality of statistical models [<xref ref-type="bibr" rid="CR12">12</xref>]. In brief, AIC measures the relative amount of information decreased by a given model, and the low AIC hence reflects the statistical model with high quality. We assessed the significance of the interaction between HCQ and other covariates on PCP risk by using the Wald test to determine the <italic>P</italic>-value of the coefficient associated with the product of the indicator of HCQ and each indicator of the covariate. All of the results were analysed using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA), and a <italic>P</italic>-value < 0.05 was considered statistically significant.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Demographic data of the enrolled population</title><p id="Par33">A total of 24,343 patients with newly-diagnosed SLE from 2001 to 2013 were enrolled. Of them, we identified 58 patients who developed PCP as PCP cases and selected 348 matched non-PCP patients as controls. We noted that PCP cases appeared to have a higher CCI (2.4 ± 1.6 vs. 1.4 ± 1.1, <italic>p</italic> < 0.01) and were more likely to have renal diseases (34.5% vs. 8.6%, p < 0.01) than non-PCP controls (Table <xref rid="Tab1" ref-type="table">1</xref>) (see dataset for details). Compared with non-PCP controls, patients with PCP tended to receive GC (96.6% vs. 69.0%, <italic>p</italic> < 0.01), and the dosage of GC was higher (36.4 ± 33.9 mg/day vs. 8.2 ± 19.8 mg/day, <italic>p</italic> < 0.01). With regards to immunosuppressants, PCP cases were more likely to receive CYC (31.0% vs. 7.2%, p < 0.01), MMF (22.4% vs. 1.4%, p < 0.01), and CYS (17.2% vs. 3.7%, p < 0.01) than controls. Conversely, PCP cases were less likely to receive HCQ (37.9% vs. 54.3%, <italic>p</italic> = 0.02) compared with non-PCP controls. (See Additional file <xref rid="MOESM1" ref-type="media">1</xref>: supplemental dataset for details).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic data and medications among enrolled subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"></th><th>Control</th><th>Case</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th><italic>n</italic> = 348</th><th><italic>n</italic> = 58</th></tr></thead><tbody><tr><td> Age, years</td><td>40.4 ± 17.9</td><td>40.4 ± 18.0</td><td>1.00</td></tr><tr><td colspan="4">Gender</td></tr><tr><td> Female</td><td>264 (75.9)</td><td>44 (75.9)</td><td>1.00</td></tr><tr><td> Male</td><td>84 (24.1)</td><td>14 (24.1)</td><td></td></tr><tr><td> Disease duration, mean ± SD year</td><td>5.7 ± 4.6</td><td>4.8 ± 4.3</td><td>0.16</td></tr><tr><td colspan="4">Comorbidities within one year before the index date</td></tr><tr><td> CCI without moderate to severe renal disease, mean ± SD</td><td>1.2 ± 0.8</td><td>1.7 ± 1.4</td><td>0.01</td></tr><tr><td> Moderate to severe renal disease</td><td>30 (8.6)</td><td>20 (34.5)</td><td>< 0.01</td></tr><tr><td colspan="4">Medications within 3 months before the indiex date</td></tr><tr><td> Trimethoprim-sulfamethaxazole</td><td>7 (2.0)</td><td>0 (0.0)</td><td>0.28</td></tr><tr><td colspan="4">Glucocorticoids</td></tr><tr><td> Usage of glucocorticoids</td><td>240 (69.0)</td><td>56 (96.6)</td><td>< 0.01</td></tr><tr><td> Prednisolone equivalent, mean ± SD mg/day<sup>a</sup></td><td>8.2 ± 19.8</td><td>36.4 ± 33.9</td><td>< 0.01</td></tr><tr><td> ≤ 5 mg/day</td><td>217 (62.4)</td><td>2 (3.4)</td><td>< 0.01</td></tr><tr><td> 5–10 mg/day</td><td>70 (20.1)</td><td>7 (12.1)</td><td></td></tr><tr><td> > 10 mg/day</td><td>61 (17.5)</td><td>49 (84.5)</td><td></td></tr><tr><td> Hydroxychloroquine</td><td>189 (54.3)</td><td>22 (37.9)</td><td>0.02</td></tr><tr><td> Cumulative dose (g)</td><td>9.2 ± 11.6</td><td>7.2 ± 12.0</td><td>0.23</td></tr><tr><td> None</td><td>159 (45.7)</td><td>36 (62.1)</td><td>0.06</td></tr><tr><td> ≤ 14 g<sup>b</sup></td><td>94 (27.0)</td><td>12 (20.7)</td><td></td></tr><tr><td> > 14 g<sup>b</sup></td><td>95 (27.3)</td><td>10 (17.2)</td><td></td></tr><tr><td> Sulfasalazine</td><td>7 (2.0)</td><td>1 (1.7)</td><td>0.88</td></tr><tr><td> Cyclophosphamide</td><td>25 (7.2)</td><td>18 (31)</td><td>< 0.01</td></tr><tr><td> Cumulative dose (g)</td><td>0.1 ± 0.5</td><td>0.9 ± 1.7</td><td>< 0.01</td></tr><tr><td> None</td><td>323 (92.8)</td><td>40 (69.0)</td><td>< 0.01</td></tr><tr><td> ≤1.4 g<sup>b</sup></td><td>17 (4.9)</td><td>6 (10.3)</td><td></td></tr><tr><td> > 1.4 g<sup>b</sup></td><td>8 (2.3)</td><td>12 (20.7)</td><td></td></tr><tr><td> Methotrexate</td><td>15 (4.3)</td><td>2 (3.4)</td><td>0.76</td></tr><tr><td> Leflunomide</td><td>0 (0.0)</td><td>0 (0.0)</td><td>NA</td></tr><tr><td> Mycophenolate mofetil /mycophenolic acid</td><td>5 (1.4)</td><td>13 (22.4)</td><td>< 0.01</td></tr><tr><td> Cyclosporine</td><td>13 (3.7)</td><td>10 (17.2)</td><td>< 0.01</td></tr><tr><td> Azathioprine</td><td>77 (22.1)</td><td>13 (22.4)</td><td>0.96</td></tr></tbody></table><table-wrap-foot><p>Data were shown as number (percentage) unless specified otherwise</p><p><sup>a</sup>Prednisolone equivalent. <sup>b</sup>Median cumulative dose. Abbreviations: IQR, interquartile range; SD, standard deviation; CCI: Charlson comorbidity index; NA, not applicable</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>The distinct risk for PCP among frequently administered medications in SLE</title><p id="Par34">We then assessed the association of the risk for PCP with each medication through conducting multivariable conditional logistical regression analyses using two models with different covariate selection methods. Determinants for the risk of PCP were largely the same between the model that forcibly entered all covariates (AIC = 85) and the model that used a stepwise selection of covariates (AIC = 82). In the stepwise selection model, determinants of the risk of PCP included moderate to severe renal disease (OR 6.73, 95% CI 1.98–22.92) and the use of GC at a dose-response manner (≤5 mg/day, reference; 5–10 mg/day, OR 25.88, 95% CI 2.97–225.33; > 10 mg/day, OR 286.58, 95% CI 28.58–> 999). (Table <xref rid="Tab2" ref-type="table">2</xref>) Furthermore, the development of PCP in lupus patients was positively associated the use of MMF/MPA (OR 50.79, 95% CI 5.32–484.77) and CYC with 3-month cumulative dose > 1.4 g (OR 11.52, 95% CI 1.97–67.39). To determine the dose-response effect of HCQ on the risk for PCP, the use of HCQ was further categorised according to the median 3-month cumulative dose. Use of HCQ with 3-month cumulative dose > 14 g decreased the risk of PCP (OR 0.20, 95% CI 0.05–0.71), and use of HCQ with 3-month cumulative dose ≤14 g tended to decrease PCP risk (aOR 0.69, 95% CI 0.21–2.24). Collectively, these data demonstrated the distinct risks for PCP among medications used to treat SLE, and we found that moderate to severe renal disease as well as the use of GC, high dose CYC and MMF were major risk factors for PCP, whereas use of HCQ tended to be a protective factor for PCP in lupus patients.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Crude and adjusted odds ratios for the association between variables and the risk of Pneumocystis Pneumonia</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"></th><th rowspan="2" colspan="2">Univariable analysis</th><th colspan="4">Multivariable analysis</th></tr><tr><th colspan="2">Forced entering</th><th colspan="2">Stepwise selection</th></tr><tr><th>OR (95% CI)</th><th>P-value</th><th>OR (95% CI)</th><th>P-value</th><th>OR (95% CI)</th><th>P-value</th></tr></thead><tbody><tr><td>Disease duration, incremental year</td><td>0.94 (0.88–1.01)</td><td>0.10</td><td>1.10 (0.92–1.32)</td><td>0.31</td><td></td><td></td></tr><tr><td>CCI without moderate to severe renal disease</td><td>1.65 (1.23–2.22)</td><td>< 0.01</td><td>1.51 (0.91–2.49)</td><td>0.12</td><td></td><td></td></tr><tr><td>Moderate to severe renal disease</td><td>4.97 (2.62–9.42)</td><td>< 0.01</td><td>7.61 (1.80–32.16)</td><td>< 0.01</td><td>6.73 (1.98–22.92)</td><td char="." align="char">< 0.01</td></tr><tr><td>Trimethoprim-sulfamethaxazole</td><td>< 0.001 (< 0.001–> 999)</td><td>0.99</td><td>< 0.001 (< 0.001–> 999)</td><td>0.99</td><td></td><td></td></tr><tr><td colspan="7">Glucocorticoids<sup>a</sup></td></tr><tr><td> ≤ 5 mg/day</td><td>Ref.</td><td></td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td> 5–10 mg/day</td><td>8.76 (1.75–43.81)</td><td>< 0.01</td><td>23.73 (2.18–258.63)</td><td>< 0.01</td><td>25.88 (2.97–225.33)</td><td char="." align="char">< 0.01</td></tr><tr><td> > 10 mg/day</td><td>90.63 (20.54–399.95)</td><td>< 0.01</td><td>997.90 (51.32–> 999)</td><td>< 0.01</td><td>286.58 (28.58–> 999)</td><td char="." align="char">< 0.01</td></tr><tr><td colspan="7">Hydroxychloroquine cumulative dose</td></tr><tr><td> None</td><td>Ref.</td><td></td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td> ≤ 14 g<sup>b</sup></td><td>0.56 (0.28–1.14)</td><td>0.11</td><td>0.56 (0.14–2.26)</td><td>0.41</td><td>0.69 (0.21–2.24)</td><td char="." align="char">0.54</td></tr><tr><td> > 14 g<sup>b</sup></td><td>0.45 (0.21–0.97)</td><td>0.04</td><td>0.12 (0.02–0.63)</td><td>0.01</td><td>0.20 (0.05–0.71)</td><td char="." align="char">0.01</td></tr><tr><td> Sulfasalazine</td><td>0.85 (0.10–7.20)</td><td>0.88</td><td>0.08 (0.00–4.71)</td><td>0.22</td><td></td><td></td></tr><tr><td colspan="7">Cyclophosphamide cumulative dose</td></tr><tr><td> None</td><td>Ref.</td><td></td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td> ≤ 1.4 g<sup>b</sup></td><td>3.18 (1.17–8.62)</td><td>0.02</td><td>0.42 (0.08–2.15)</td><td>0.30</td><td>0.64 (0.14–3.01)</td><td char="." align="char">0.58</td></tr><tr><td> > 1.4 g<sup>b</sup></td><td>21.87 (6.00–79.81)</td><td>< 0.01</td><td>12.01 (1.42–101.58)</td><td>0.02</td><td>11.52 (1.97–67.39)</td><td char="." align="char">< 0.01</td></tr><tr><td> Methotrexate / Leflunomide</td><td>0.79 (0.17–3.62)</td><td>0.76</td><td>0.29 (0.01–7.94)</td><td>0.47</td><td></td><td></td></tr><tr><td> Mycophenolate mofetil/mycophenolic acid</td><td>34.11 (7.65–152.19)</td><td>< 0.01</td><td>38.07 (0.88–> 999)</td><td>0.06</td><td>50.79 (5.32–484.77)</td><td char="." align="char">< 0.01</td></tr><tr><td> Cyclosporine</td><td>5.03 (2.12–11.92)</td><td>< 0.01</td><td>3.83 (0.64–23.05)</td><td>0.14</td><td></td><td></td></tr><tr><td> Azathioprine</td><td>1.02 (0.53–1.96)</td><td>0.96</td><td>0.57 (0.15–2.26)</td><td>0.43</td><td></td><td></td></tr><tr><td> AIC</td><td></td><td></td><td>85</td><td></td><td>82</td><td></td></tr></tbody></table><table-wrap-foot><p>Adjusted for age and gender. <sup>a</sup>Prednisolone equivalent. <sup>b</sup>Median cumulative dose. AIC, Akaike information criterion</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Subgroup analyses of the association between the risk for PCP and HCQ usage</title><p id="Par35">Subgroup analyses were conducted to test the consistency of the association between HCQ and PCP risk and to examine the presence of interaction effect between HCQ and other relevant variables. We further divided the subjects by age (> 40 and ≤ 40 years), sex, moderate to severe renal disease, and the usage of immunosuppressants (CYC, MMF/MPA, CS or AZA) (Table <xref rid="Tab3" ref-type="table">3</xref>). No interaction effect was noted, and the protective effect of HCQ higher than median dose against PCP appeared to be prominent in those with young age (≤40 years), were female, without renal diseases and receiving GC higher than 10 mg/day. Collectively, these data demonstrated a consistently inverse correlation between HCQ and the risk PCP in patients with SLE.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Subgroup analyses for the correlation between hydroxychloroquine and risk of pneumocystis pneumonia using multivariable conditional logistic regression models</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Groups</th><th rowspan="3">None</th><th colspan="4">Hydroxychloroquine 3-month cumulative dose</th><th rowspan="3"></th></tr><tr><th colspan="2">≤14 g<sup>a</sup></th><th colspan="2">> 14 g<sup>a</sup></th></tr><tr><th>OR (95% CI)</th><th>P-value</th><th>OR (95% CI)</th><th>P-value</th></tr></thead><tbody><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td char="." align="char">0.052</td></tr><tr><td> Age ≤ 40 years</td><td>Ref.</td><td>0.89 (0.26–3.07)</td><td>0.85</td><td>0.10 (0.02–0.54)</td><td>0.01</td><td></td></tr><tr><td> Age > 40 years</td><td>Ref.</td><td>0.24 (0.04–1.31)</td><td>0.10</td><td>0.60 (0.15–2.49)</td><td>0.49</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td char="." align="char">0.42</td></tr><tr><td> Female</td><td>Ref.</td><td>0.74 (0.27–2.07)</td><td>0.57</td><td>0.26 (0.08–0.80)</td><td>0.02</td><td></td></tr><tr><td> Male</td><td>Ref.</td><td>0.13 (0.01–1.94)</td><td>0.14</td><td>0.55 (0.02–16.59)</td><td>0.73</td><td></td></tr><tr><td>Moderate to severe renal disease</td><td></td><td></td><td></td><td></td><td></td><td char="." align="char">0.41</td></tr><tr><td> No</td><td>Ref.</td><td>0.35 (0.11–1.12)</td><td>0.08</td><td>0.22 (0.07–0.73)</td><td>0.01</td><td></td></tr><tr><td> Yes</td><td>Ref.</td><td>0.71 (0.05–11.11)</td><td>0.80</td><td>0.03 (< 0.001–1.19)</td><td>0.06</td><td></td></tr><tr><td>Glucocorticoids<sup>b</sup></td><td></td><td></td><td></td><td></td><td></td><td char="." align="char">0.31</td></tr><tr><td> ≤10 mg/day</td><td>Ref.</td><td>0.25 (0.05–1.38)</td><td>0.11</td><td>0.50 (0.10–2.41)</td><td>0.39</td><td></td></tr><tr><td> > 10 mg/day</td><td>Ref.</td><td>0.95 (0.27–3.35)</td><td>0.94</td><td>0.17 (0.04–0.68)</td><td>0.01</td><td></td></tr><tr><td>Immunosuppressants<sup>c</sup></td><td></td><td></td><td></td><td></td><td></td><td char="." align="char">0.83</td></tr><tr><td> No</td><td>Ref.</td><td>< 0.001 (< 0.001–> 999)</td><td>0.94</td><td>0.09 (0.00–1.67)</td><td>0.11</td><td></td></tr><tr><td> Yes</td><td>Ref.</td><td>1.09 (0.37–3.19)</td><td>0.88</td><td>0.39 (0.13–1.20)</td><td>0.10</td><td></td></tr></tbody></table><table-wrap-foot><p>Covariates in the conditional logistric regression models included Charlson comorbidity index without moderate to renal disease, moderate to severe renal disease, methotrexate/leflunomide, sulfasalazine, immunosuppressants and trimethoprim-sulfamethaxazole excluding the covariate that was used to stratify subjects. <sup>a</sup>Median cumulative dose. <sup>b</sup>Prednisolone equivalent. <sup>c</sup>Immunosuppressants include cyclosporine, azathioprine, cyclophosphamide, and mycophenolate mofetil/mycophenolic acid</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par36">To the best of our knowledge, the present study is the first research to address the association between HCQ use and the risk for PCP in lupus patients using a population-based claim database. We found that the use of HCQ with a 3-month cumulative dose of > 14 g was associated with a reduced risk of PCP, whereas the use of GC, CYC and MMF/MPA was associated with an increased risk for PCP in lupus patients. These findings indicated the distinct risk for PCP in lupus patients receiving GC and immunosuppressants and suggested a potential protective role of HCQ against PCP.</p><p id="Par37">HCQ was originally developed as an antimalarial medication and is currently widely used as an immunomodulation agent for autoimmune diseases, mainly SLE, RA and Sjögren’s syndrome [<xref ref-type="bibr" rid="CR13">13</xref>]. In addition to the antimalarial properties, HCQ also has antibacterial activities, which were mainly exerted by pH-dependent iron depletion and by an increased pH of phagosome, which in turn inhibit the growth of intracellular organisms [<xref ref-type="bibr" rid="CR4">4</xref>]. Owing to the aforementioned antibacterial effect, HCQ has been found to be associated with a decreased risk of major bacterial infections in lupus patients [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In addition to the antimalarial and antibacterial effects, HCQ also exhibits antifungal activities. Henriet et al., conducting an in vivo study with <italic>Aspergillus fumigatus and Aspergillus nidulans</italic>, demonstrated that chloroquine may increase the antifungal activity of leucocytes isolated in those with chronic granulomatous disease (CGD) at a low concentration through regulating the production of interleukin-1β and tumor necrosis factor-α [<xref ref-type="bibr" rid="CR16">16</xref>]. Another in vitro study also found the synergistic effect of chloroquine and fluconazole against fluconazole-resistant <italic>Candida spp</italic>. including <italic>Candida tropicalis</italic> as well as <italic>Candida krusei</italic> [<xref ref-type="bibr" rid="CR5">5</xref>]. Although data regarding <italic>Pneumocystis jirovecii</italic> are still lacking, Podrebarac et al. reported two subjects with SLE receiving high-dose GC developed PCP shortly after discontinuation of HCQ [<xref ref-type="bibr" rid="CR17">17</xref>]. Taken together, these evidence highlight the anti-fungal effect of HCQ and at least partly explain the protective effect of HCQ against PCP in lupus patients as shown in this study.</p><p id="Par38">The prevalence of PCP in lupus patients has varied over the past two decades. Gupta D. et al., analyzing 18 studies conducted in the United States between 1987 and 2006, found that merely 0.16% (121/76,156) of patients with SLE had PCP [<xref ref-type="bibr" rid="CR18">18</xref>]. Recently, Kapoor TM et al. reported that approximately 0.45% (9/2000) of hospitalized patients with SLE had PCP using data collected from a database for the period 2000–2014 at Columbia University Medical Center-New York Presbyterian Hospital [<xref ref-type="bibr" rid="CR19">19</xref>]. In the present study, we found that 0.24% (58/24,348) of patients with SLE between 2001 and 2013 had PCP in Taiwan. In line with our data, Weng CT et al., investigating 858 hospitalised lupus patient in southern Taiwan, found that only 0.58% (5/858) of them had PCP with identified Pneumocystis organisms in the lung (2 by lung biopsy and the other three by bronchoalveolar lavage) [<xref ref-type="bibr" rid="CR20">20</xref>]. Taken together, the diagnosis of PCP appears to have increased gradually in the past two decades; however, the prevalence remains low. Given that we used a conservative definition for PCP, including both ICD-9-CM codes of PCP and medication for PCP to define the diagnosis of PCP, we may have underestimated, rather than overestimated, the prevalence of PCP infection in the present Taiwanese research.</p><p id="Par39">In the present study, we identified an elevated risk of PCP in lupus patients taking MMF/MPA or in taking CYC with 3-month cumulative dose > 1.4 g. However, the use of CS, AZA or MTX was not significantly associated with the risk for PCP. Indeed, discrepant findings have been noted in the risk for infection among immunosuppressants in lupus patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. MMF was initially reported to have fewer severe infections as the induction therapy for lupus nephritis when compared with CYC [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. However, one recently published study conducted by Feldman CH et al., using the Medicaid beneficiaries with patients with SLE in 28 U.S. states, found that the risk for severe infections was not increased among new users of CYC and MMF/MPA, and AZA [<xref ref-type="bibr" rid="CR21">21</xref>]. Similarly, Mok CC et al. conducted a long-term follow-up research among 803 patients with SLE and showed that CYC and MMF/MPA had similar impacts on survival [<xref ref-type="bibr" rid="CR24">24</xref>]. However, it is somehow difficult to disentangle the effects of the complex interaction among disease activities, the sequential/combinational usage of immunosuppressants, and dosage of each medication on the risks for PCP. Therefore, CS and AZA did not confer any significant independent risks for PCP in this study, although these two medications tended to increase the risk of PCP in the univariable analysis. Intriguingly, in the aforementioned study conducted by Mok CC et al., the use of HCQ had a survival benefit in patients with SLE (HR 0.59, 95% CI 0.37–0.93) [<xref ref-type="bibr" rid="CR24">24</xref>]. Moreover, Feldman CH et al., using Medicaid database between 2000 and 2006, also found that HCQ user had a decreased risk of infections than non-user (HR 0.73, 95% CI 0.68–0.77) [<xref ref-type="bibr" rid="CR10">10</xref>], and these findings are largely consistent with our findings in the present study.</p><p id="Par40">Moderate to severe renal disease was an independent risk for PCP in the present study. In line with our findings, Feldman CH et al., analyzing 33,565 patients with SLE and 7113 with lupus nephritis, found that the incidence rate of serious infections requiring hospitalization per 100 person-years was 10.8 in SLE and 23.9 in those with lupus nephritis [<xref ref-type="bibr" rid="CR10">10</xref>]. Although we could not specify lupus nephritis using ICD, the moderate to severe renal disease in lupus patients should be reasonably attributed to lupus nephritis given that underlying moderate to severe renal disease is uncommon in subjects aged 40. The high risk for PCP in lupus patients with moderate to severe renal disease highlights that lupus patients with renal involvement are particularly vulnerable to infectious diseases, including PCP. A number of studies have explored the efficacy and safety profile of using trimethoprim-sulfamethoxazole as PCP prophylaxis in high-risk lupus patients, particularly those receiving medium-to-high dose GC [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, there is currently no consensus regarding routine PCP prophylaxis in lupus patients, and we think PCP prophylaxis might potentially be feasible in high-risk patients [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par41">There are limitations in this study. First, our results were derived from a population-based claim database in Taiwan; therefore, further investigations involving other populations are needed for the generalizability. Second, we could not assess the causality of HCQ-associated reduced risk for PCP; however, the finding of this study warrant more mechanistic studies. Third, the accuracy of diagnoses is a concern in the claim database. However, we think that regular quality control surveys of NHIRD among all medical facilities by the BNHI has much improved the accuracy of coding in NHIRD [<xref ref-type="bibr" rid="CR27">27</xref>], and bias attributed by the misclassification was hence minimised. Additionally, the prevalence of PCP infection in the present Taiwanese research was quite similar to those in other studies [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec15"><title>Conclusions</title><p id="Par42">PCP is a life-threatening fungal infection with an increasing prevalence in patients with SLE. We have identified a potentially protective effect of HCQ against PCP and demonstrated the distinct risks for PCP conferred by GC and various immunosuppressants in lupus patients. The decreased risk of PCP in lupus patients receiving HCQ as we showed should be clinically relevant, such as the prescription of HCQ for lupus patients with a high risk for PCP and the less indicated for PCP prophylactics in patients already receiving HCQ. The distinct risks for PCP among GC and immunosuppressants should be taken into account with regards to the vigilance for PCP and the implementation of PCP prophylaxis in lupus patients. Further mechanistic studies are required to address the underlying mechanisms.</p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec16"><p><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12879_2020_4826_MOESM1_ESM.xlsx"><caption><p><bold>Additional file 1.</bold> Dataset. raw data of the study</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AZA</term><def><p id="Par5">Azathioprine</p></def></def-item><def-item><term>BNHI</term><def><p id="Par6">Bureau of National Health Insurance</p></def></def-item><def-item><term>CCI</term><def><p id="Par7">Charlson comorbidity index</p></def></def-item><def-item><term>CI</term><def><p id="Par8">Confidence intervals</p></def></def-item><def-item><term>CS</term><def><p id="Par9">Cyclosporin</p></def></def-item><def-item><term>CYC</term><def><p id="Par10">Cyclophosphamide</p></def></def-item><def-item><term>GC</term><def><p id="Par11">Glucocorticoids</p></def></def-item><def-item><term>HCQ</term><def><p id="Par12">Hydroxychloroquine</p></def></def-item><def-item><term>ICD</term><def><p id="Par13">International Classification of Diseases</p></def></def-item><def-item><term>MMF</term><def><p id="Par14">Mycophenolate mofetil</p></def></def-item><def-item><term>MPA</term><def><p id="Par15">Mycophenolic acid</p></def></def-item><def-item><term>NHI</term><def><p id="Par16">National Health Insurance</p></def></def-item><def-item><term>NHIRD</term><def><p id="Par17">National Health Insurance Research Database</p></def></def-item><def-item><term>NSAID</term><def><p id="Par18">Non-steroid anti-inflammatory drugs</p></def></def-item><def-item><term>OR</term><def><p id="Par19">Odds ratios</p></def></def-item><def-item><term>PCP</term><def><p id="Par20">Pneumocystis pneumonia</p></def></def-item><def-item><term>RA</term><def><p id="Par21">Rheumatoid arthritis</p></def></def-item><def-item><term>RCIPD</term><def><p id="Par22">Registry for Catastrophic Illness Patient Database</p></def></def-item><def-item><term>SLE</term><def><p id="Par23">Systemic lupus erythematosus</p></def></def-item><def-item><term>SSZ</term><def><p id="Par24">Sulfasalazine</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher’s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Kai-Jieh Yeo and Hsin-Hua Chen contributed equally to this work.</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s12879-020-4826-1.</p></sec><ack><title>Acknowledgements</title><p>This study is based on the data from the NHIRD maintained and regulated by the Data Science Centre of the Ministry of Health and Welfare (Registered number 101095 and 102148). The interpretation of the data and conclusions of the study do not represent those of NHIRD. The authors thank the Biostatistics Task Force and Healthcare Service Research Center of Taichung Veterans General Hospital for the assistance with the analyses of this study.</p></ack><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>Designed and conceived the study: KJY, HHC, and WCC. Acquired the study data: HHC and CHL. Contributed to the materials or analysis tools: WCC, HHC, KJY, CHL, YMC, and DYC. Wrote the manuscript: KJY, HHC, CML, and WCC. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The present study was not funded.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All of the data in the present research are contained in the article and the supplementary profile.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par43">The present study was approved by the Institutional Review Board of Taichung Veterans General Hospital, Taiwan (CE14149B-3). Written informed consent was waived given that all of the data were de-identified.</p></notes><notes><title>Consent for publication</title><p id="Par44">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par45">The authors of the study declare that they have no financial or commercial conflicts of interest with regards to this submission.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillatre</surname><given-names>P</given-names></name><name><surname>Decaux</surname><given-names>O</given-names></name><name><surname>Jouneau</surname><given-names>S</given-names></name><name><surname>Revest</surname><given-names>M</given-names></name><name><surname>Gacouin</surname><given-names>A</given-names></name><name><surname>Robert-Gangneux</surname><given-names>F</given-names></name><name><surname>Fresnel</surname><given-names>A</given-names></name><name><surname>Guiguen</surname><given-names>C</given-names></name><name><surname>Le Tulzo</surname><given-names>Y</given-names></name><name><surname>Jego</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients</article-title><source>Am J Med</source><year>2014</year><volume>127</volume><issue>12</issue><fpage>1242 e1211</fpage><lpage>1242 e1247</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2014.07.010</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>JJ</given-names></name><name><surname>Lueck</surname><given-names>C</given-names></name><name><surname>Ziesing</surname><given-names>S</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Haller</surname><given-names>H</given-names></name><name><surname>Gottlieb</surname><given-names>J</given-names></name><name><surname>Eder</surname><given-names>M</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Hoeper</surname><given-names>MM</given-names></name><name><surname>Scherag</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years</article-title><source>Crit Care</source><year>2018</year><volume>22</volume><issue>1</issue><fpage>307</fpage><pub-id pub-id-type="doi">10.1186/s13054-018-2221-8</pub-id><pub-id pub-id-type="pmid">30454031</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pryor</surname><given-names>BD</given-names></name><name><surname>Bologna</surname><given-names>SG</given-names></name><name><surname>Kahl</surname><given-names>LE</given-names></name></person-group><article-title>Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus</article-title><source>Arthritis Rheum</source><year>1996</year><volume>39</volume><issue>9</issue><fpage>1475</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1002/art.1780390906</pub-id><pub-id pub-id-type="pmid">8814058</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolain</surname><given-names>JM</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century</article-title><source>Int J Antimicrob Agents</source><year>2007</year><volume>30</volume><issue>4</issue><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.05.015</pub-id><pub-id pub-id-type="pmid">17629679</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>R</given-names></name></person-group><article-title>Synergistic activity of chloroquine with fluconazole against fluconazole-resistant isolates of Candida species</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>2</issue><fpage>1365</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1128/AAC.04417-14</pub-id><pub-id pub-id-type="pmid">25512426</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gigliotti</surname><given-names>F</given-names></name><name><surname>Bhagwat</surname><given-names>SP</given-names></name><name><surname>George</surname><given-names>TC</given-names></name><name><surname>Wright</surname><given-names>TW</given-names></name></person-group><article-title>Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia</article-title><source>PLoS Pathog</source><year>2010</year><volume>6</volume><issue>8</issue><fpage>e1001058</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1001058</pub-id><pub-id pub-id-type="pmid">20808846</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunokawa</surname><given-names>T</given-names></name><name><surname>Yokogawa</surname><given-names>N</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Sugii</surname><given-names>S</given-names></name><name><surname>Nishino</surname><given-names>J</given-names></name><name><surname>Gosho</surname><given-names>M</given-names></name><name><surname>Wagatsuma</surname><given-names>Y</given-names></name><name><surname>Tohma</surname><given-names>S</given-names></name></person-group><article-title>Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: a nested case-control study</article-title><source>Semin Arthritis Rheum</source><year>2019</year><volume>48</volume><issue>4</issue><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2018.05.013</pub-id><pub-id pub-id-type="pmid">30057321</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">The National Health Insurance Statistics 2015. In<italic>.</italic>: National Health Insurance Administration, Ministry of Health and Welfare, Taiwan, R.O.C.; 2015.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maschmeyer</surname><given-names>G</given-names></name><name><surname>Helweg-Larsen</surname><given-names>J</given-names></name><name><surname>Pagano</surname><given-names>L</given-names></name><name><surname>Robin</surname><given-names>C</given-names></name><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Schellongowski</surname><given-names>P</given-names></name><collab>The European conference on infections in leukemia ajvoTEGfB, marrow transplantation TEOfR, treatment of Cancer tIIHS, the European L</collab></person-group><article-title>ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients</article-title><source>J Antimicrob Chemother</source><year>2016</year><volume>71</volume><issue>9</issue><fpage>2405</fpage><lpage>2413</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw158</pub-id><pub-id pub-id-type="pmid">27550993</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>CH</given-names></name><name><surname>Hiraki</surname><given-names>LT</given-names></name><name><surname>Winkelmayer</surname><given-names>WC</given-names></name><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Franklin</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Costenbader</surname><given-names>KH</given-names></name></person-group><article-title>Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis</article-title><source>Arthritis Rheumatol</source><year>2015</year><volume>67</volume><issue>6</issue><fpage>1577</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1002/art.39070</pub-id><pub-id pub-id-type="pmid">25772621</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Cherkin</surname><given-names>DC</given-names></name><name><surname>Ciol</surname><given-names>MA</given-names></name></person-group><article-title>Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases</article-title><source>J Clin Epidemiol</source><year>1992</year><volume>45</volume><issue>6</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(92)90133-8</pub-id><pub-id pub-id-type="pmid">1607900</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrieze</surname><given-names>SI</given-names></name></person-group><article-title>Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC)</article-title><source>Psychol Methods</source><year>2012</year><volume>17</volume><issue>2</issue><fpage>228</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1037/a0027127</pub-id><pub-id pub-id-type="pmid">22309957</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avina-Zubieta</surname><given-names>JA</given-names></name><name><surname>Galindo-Rodriguez</surname><given-names>G</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Suarez-Almazor</surname><given-names>ME</given-names></name><name><surname>Russell</surname><given-names>AS</given-names></name></person-group><article-title>Long-term effectiveness of antimalarial drugs in rheumatic diseases</article-title><source>Ann Rheum Dis</source><year>1998</year><volume>57</volume><issue>10</issue><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1136/ard.57.10.582</pub-id><pub-id pub-id-type="pmid">9893568</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Olivares</surname><given-names>N</given-names></name><name><surname>Ruiz-Arruza</surname><given-names>I</given-names></name><name><surname>Martinez-Berriotxoa</surname><given-names>A</given-names></name><name><surname>Egurbide</surname><given-names>MV</given-names></name><name><surname>Aguirre</surname><given-names>C</given-names></name></person-group><article-title>Predictors of major infections in systemic lupus erythematosus</article-title><source>Arthritis Res Ther</source><year>2009</year><volume>11</volume><issue>4</issue><fpage>R109</fpage><pub-id pub-id-type="doi">10.1186/ar2764</pub-id><pub-id pub-id-type="pmid">19604357</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siso</surname><given-names>A</given-names></name><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Bove</surname><given-names>A</given-names></name><name><surname>Brito-Zeron</surname><given-names>P</given-names></name><name><surname>Soria</surname><given-names>N</given-names></name><name><surname>Munoz</surname><given-names>S</given-names></name><name><surname>Testi</surname><given-names>A</given-names></name><name><surname>Plaza</surname><given-names>J</given-names></name><name><surname>Sentis</surname><given-names>J</given-names></name><name><surname>Coca</surname><given-names>A</given-names></name></person-group><article-title>Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival</article-title><source>Lupus</source><year>2008</year><volume>17</volume><issue>4</issue><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1177/0961203307086503</pub-id><pub-id pub-id-type="pmid">18413408</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriet</surname><given-names>SS</given-names></name><name><surname>Jans</surname><given-names>J</given-names></name><name><surname>Simonetti</surname><given-names>E</given-names></name><name><surname>Kwon-Chung</surname><given-names>KJ</given-names></name><name><surname>Rijs</surname><given-names>AJ</given-names></name><name><surname>Hermans</surname><given-names>PW</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>de Jonge</surname><given-names>MI</given-names></name><name><surname>Warris</surname><given-names>A</given-names></name></person-group><article-title>Chloroquine modulates the fungal immune response in phagocytic cells from patients with chronic granulomatous disease</article-title><source>J Infect Dis</source><year>2013</year><volume>207</volume><issue>12</issue><fpage>1932</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit103</pub-id><pub-id pub-id-type="pmid">23482646</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podrebarac</surname><given-names>TA</given-names></name><name><surname>Jovaisas</surname><given-names>A</given-names></name><name><surname>Karsh</surname><given-names>J</given-names></name></person-group><article-title>Pneumocystis carinii pneumonia after discontinuation of hydroxychloroquine in 2 patients with systemic lupus erythematosus</article-title><source>J Rheumatol</source><year>1996</year><volume>23</volume><issue>1</issue><fpage>199</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">8838542</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Zachariah</surname><given-names>A</given-names></name><name><surname>Roppelt</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>AM</given-names></name><name><surname>Gruber</surname><given-names>BL</given-names></name></person-group><article-title>Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature</article-title><source>J Clin Rheumatol</source><year>2008</year><volume>14</volume><issue>5</issue><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1097/RHU.0b013e31817a7e30</pub-id><pub-id pub-id-type="pmid">18679133</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>TM</given-names></name><name><surname>Mahadeshwar</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Bathon</surname><given-names>J</given-names></name><name><surname>Giles</surname><given-names>J</given-names></name><name><surname>Askanase</surname><given-names>A</given-names></name></person-group><article-title>Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse</article-title><source>Lupus</source><year>2017</year><volume>26</volume><issue>14</issue><fpage>1473</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1177/0961203317703494</pub-id><pub-id pub-id-type="pmid">28399687</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>CT</given-names></name><name><surname>Liu</surname><given-names>MF</given-names></name><name><surname>Weng</surname><given-names>MY</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name><name><surname>Wang</surname><given-names>MC</given-names></name><name><surname>Lin</surname><given-names>WC</given-names></name><name><surname>Ou</surname><given-names>CY</given-names></name><name><surname>Lai</surname><given-names>WW</given-names></name><name><surname>Hsu</surname><given-names>SC</given-names></name><name><surname>Chao</surname><given-names>SC</given-names></name><etal></etal></person-group><article-title>Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan</article-title><source>J Clin Rheumatol</source><year>2013</year><volume>19</volume><issue>5</issue><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1097/RHU.0b013e31829d5017</pub-id><pub-id pub-id-type="pmid">23872548</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>CH</given-names></name><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Winkelmayer</surname><given-names>WC</given-names></name><name><surname>Guan</surname><given-names>H</given-names></name><name><surname>Franklin</surname><given-names>JM</given-names></name><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Costenbader</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name></person-group><article-title>Comparative rates of serious infections among patients with systemic lupus Erythematosus receiving immunosuppressive medications</article-title><source>Arthritis Rheumatol</source><year>2017</year><volume>69</volume><issue>2</issue><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1002/art.39849</pub-id><pub-id pub-id-type="pmid">27589220</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzler</surname><given-names>EM</given-names></name><name><surname>Dooley</surname><given-names>MA</given-names></name><name><surname>Aranow</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>MY</given-names></name><name><surname>Buyon</surname><given-names>J</given-names></name><name><surname>Merrill</surname><given-names>JT</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Gilkeson</surname><given-names>GS</given-names></name><name><surname>Wallace</surname><given-names>DJ</given-names></name><name><surname>Weisman</surname><given-names>MH</given-names></name><etal></etal></person-group><article-title>Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><issue>21</issue><fpage>2219</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043731</pub-id><pub-id pub-id-type="pmid">16306519</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LL</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>LN</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>ZL</given-names></name></person-group><article-title>Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials</article-title><source>Drugs</source><year>2012</year><volume>72</volume><issue>11</issue><fpage>1521</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.2165/11635030-000000000-00000</pub-id><pub-id pub-id-type="pmid">22818016</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Tse</surname><given-names>SM</given-names></name><name><surname>Chan</surname><given-names>KL</given-names></name><name><surname>Ho</surname><given-names>LY</given-names></name></person-group><article-title>Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort</article-title><source>Lupus</source><year>2018</year><volume>27</volume><issue>5</issue><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1177/0961203317739129</pub-id><pub-id pub-id-type="pmid">29087260</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Curtis</surname><given-names>JR</given-names></name><name><surname>Moon</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>YW</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name></person-group><article-title>Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids</article-title><source>Ann Rheum Dis</source><year>2018</year><volume>77</volume><issue>5</issue><fpage>644</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2017-211796</pub-id><pub-id pub-id-type="pmid">29092853</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Curtis</surname><given-names>JR</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name></person-group><article-title>Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole</article-title><source>Arthritis Res Ther</source><year>2019</year><volume>21</volume><issue>1</issue><fpage>207</fpage><pub-id pub-id-type="doi">10.1186/s13075-019-1996-6</pub-id><pub-id pub-id-type="pmid">31521185</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>TM</given-names></name></person-group><article-title>Taiwan’s new national health insurance program: genesis and experience so far</article-title><source>Health Aff (Millwood)</source><year>2003</year><volume>22</volume><issue>3</issue><fpage>61</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.22.3.61</pub-id><pub-id pub-id-type="pmid">12757273</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000042 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000042 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7011312
|texte= Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32041539" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |